Minapharm Pharmaceuticals (CAI:MIPH) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
43 GF Score
Price E£879.95
GF Value E£375.05
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

CAI:MIPH
43GF Score
Minapharm Pharmaceuticals CAI:MIPH
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£879.95 is trading 134.6% above its estimated GF Value™ of E£375.05. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Total Noninterest Expense:
  • GF Value™: E£375.05 vs. price of E£879.95 (134.6% above fair value)
  • GF Score™: 43/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is an Egyptian pharmaceutical company engaged in the development, manufacturing, and marketing of human and veterinary medicines, as well as dietary supplements and herbal products. Its portfolio spans therapeutic areas including cardiology, gastroenterology, dermatology, ophthalmology, orthopedics, and uro-gynecology, alongside biogenerics produced through its biotechnology operations. The company manufactures finished dosage forms and active ingredients at its facilities in Egypt and serves patients and healthcare providers across the Middle East and North Africa, with exports to additional international markets. Revenue is generated primarily through the sale of branded generic and biogeneric pharmaceuticals, supplemented by contract manufacturing and licensing arrangements with multinational partners. Minapharm also operates through subsidiaries focused on biopharmaceutical production and diagnostic services, supporting its position as one of Egypt's larger domestic drugmakers.
43GF Score

Get the complete analysis for CAI:MIPH

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£879.95
Price
E£375.05
GF Value